Cogent Biosciences Return on Equity

Cogent Biosciences (COGT) currently reports a ROE of -70.85%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Cogent Biosciences's ROE history and peer comparisons.

Cogent Biosciences's ROE of -70.85% is lower than the Healthcare sector average of 20.86%. That is roughly 439.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cogent Biosciences's current -70.85% should be judged against Healthcare norms (sector average: 20.86%) and against COGT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -70.85%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Cogent Biosciences, and consider following COGT for alerts when major investors trade the stock.

Cogent Biosciences is classified in the Healthcare sector. On ROE, it currently shows -70.85% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing COGT with unrelated industries.